23 Jan 2024 – We are thrilled to announce the successful conclusion of our collaborative agreement with iCare, marking a significant milestone in the world of eye care. The partnership will result in both companies working together to seamlessly integrate SELENA+ our AI for retinal diseases with iCare’s proprietary platform, ILLUME.
ILLUME, developed by iCare, is a cutting-edge platform meticulously designed to align with iCARE’s vision of providing effortless, accurate, and reliable eye care solutions. It seamlessly integrates with iCare’s range of confocal imaging systems, creating a comprehensive patient journey from home care to primary to tertiary care.
Confocal imaging, a crucial component of ILLUME, is renowned for enhancing fundus image quality by blocking unwanted backscattered light from external structures. This results in unparalleled image sharpness and resolution.
SELENA+ represents the pinnacle of AI technology in the field of eye care. It possesses the remarkable ability to detect diabetic retinopathy, glaucoma, and age-related macular degeneration in fundus images. Notably, SELENA+ is deployed in over 30 territories worldwide and holds the distinction of being one of the pioneering AI solutions in a National Diabetic Retinopathy Screening Program.
Through this groundbreaking collaboration, we aim to showcase the efficiency and effectiveness of AI technology within a well-crafted platform. Our collective efforts are focused on optimizing workflows and streamlining processes in eye care. The ultimate goal is to effectively prevent blindness and transform the way we care for our patients.
For media inquiries, please contact firstname.lastname@example.org
Comments are closed.